Onconetix, Inc. ONCO
focused on the research, development, and commercialization of innovative solutions for men's health and oncology. Through our
acquisition of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally
developed by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation ("IVDR"), which
we anticipate will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- Switzerland
- United Kingdom
| Region | FY2025 |
|---|---|
| Switzerland | $796.6K |
| United Kingdom | $18.8K |
As the company reported it, from the “Segment Information - Schedule of Revenue by Geographical Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $815.4K | $2.5M | $58.5K | — | — | — |
| Cost of revenue | $182.5K | $1.5M | $1.2M | — | — | — |
| Gross profit | $632.9K | $1.1M | -$1.1M | — | — | — |
| R&D | — | $154.4K | $1.9M | $4.1M | $1.3M | — |
| SG&A | $7.0M | $11.2M | $14.8M | $9.4M | $2.1M | — |
| Total operating expenses | $18.5M | $57.5M | $34.9M | $13.5M | $3.4M | — |
| Operating income | -$17.9M | -$56.5M | -$36.0M | -$13.5M | -$3.4M | — |
| Interest expense | $751.0K | $873.4K | $671.6K | — | — | — |
| Pre-tax income | -$14.0M | -$59.7M | -$37.4M | -$13.4M | $675.73B | — |
| Income tax | $525 | $1.0M | $12.6K | $3.16T | $675.73B | — |
| Net income | -$14.0M | -$58.7M | -$37.4M | -$13.4M | -$3.4M | — |
| EPS, basic | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 | — |
| EPS, diluted | -16.56 | -1,823.39 | -87.45 | -1.10 | -1.26 | — |
| Shares, diluted (wtd. avg.) | 937,690 | 32,301 | 427,784 | 12.3M | 3.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $5.2M | $646.5K | $4.6M | $25.8M | $1.9M | $4.3M |
| Receivables | $296.9K | $25.7K | $149.7K | — | — | — |
| Inventory | $150.0K | $64.1K | $364.1K | — | — | — |
| Total current assets | $6.1M | $950.3K | $5.8M | $26.3M | $3.1M | — |
| Property, plant and equipment | $37.1K | $62.9K | $60.7K | $14.1K | $11.5K | — |
| Goodwill | $18.5M | $27.0M | $55.7M | — | — | — |
| Other intangibles | — | — | $25.4M | — | — | — |
| Total assets | $24.9M | $28.2M | $87.5M | $26.3M | $3.1M | — |
| Accounts payable | $1.8M | $3.8M | $5.3M | $1.5M | $582.6K | — |
| Total current liabilities | $9.1M | $18.3M | $17.2M | $3.9M | $1.6M | — |
| Total liabilities | $9.2M | $18.6M | $21.9M | $3.9M | $1.6M | — |
| Retained earnings | -$131.2M | -$115.7M | -$56.8M | -$19.4M | -$6.0M | — |
| Total equity | $15.8M | $8.5M | $1.4M | $22.4M | $1.4M | $4.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.7M | -$10.5M | -$13.6M | -$8.7M | -$2.0M | — |
| Depreciation and amortisation | $15.0K | $22.0K | $7.0K | $6.8K | $4.9K | — |
| Stock-based compensation | $74.3K | $438.7K | $329.8K | $2.0M | $130.1K | — |
| Capital expenditure | — | $28.5K | $3.3K | $9.3K | $1.9K | — |
| Investing cash flow | — | -$28.5K | -$8.6M | -$32.7K | -$1.9K | — |
| Financing cash flow | $14.5M | $6.7M | $1.0M | $32.5M | -$334.2K | — |
| Buybacks | — | — | $59.0K | $566.8K | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-027725.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $58.5K | $2.5M | $815.4K |
| Gross profit | — | — | — | -$1.1M | $1.1M | $632.9K |
| Net income | — | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed Item 5.03
- Other event Item 8.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |